Cresco Labs Inc. (CRLBF)

↓ Download CSV

CIK 0001832928 · OTC · Medicinal Chemicals & Botanical Products

  • Sector Manufacturing
  • Incorporated A1
  • Fiscal year ends Dec 31

In fiscal 2025, Cresco Labs Inc. reported revenue of $655.85M, down 9.5% from the prior year. The company ran a net loss, with a net margin of -20.6% and a gross margin of 49.5%. It held $1.20B in total assets against $944.80M in total liabilities.

Key ratios (FY2025)

49.5%
Gross margin
-4.3%
Operating margin
-20.6%
Net margin
-53.6%
Return on equity
-9.5%
Revenue growth (YoY)
Metric (FY)2025202420232022
Revenue$655.85M$724.34M$770.88M
Cost of Revenue$331.28M$359.89M$408.52M
Gross Profit$324.57M$364.45M$362.37M
Operating Income-$27.99M$107.29M-$87.82M
Net Income-$135.41M-$74.44M-$175.52M
EPS (Diluted)$-0.38$-0.22$-0.54
Total Assets$1.20B$1.36B$1.36B
Total Liabilities$944.80M$967.18M$930.40M
Shareholders' Equity$252.50M$388.18M$428.07M$587.68M
Cash & Equivalents$57.90M$137.56M$103.43M
Operating Cash Flow$72.89M$132.48M$58.56M
Capital Expenditures$35.14M$19.49M$55.38M
Shares Outstanding355.01M345.47M323.82M